Q1 2025 EPS Estimates for Bausch Health Companies Inc. (NYSE:BHC) Increased by Analyst

Bausch Health Companies Inc. (NYSE:BHC) – Zacks Research boosted their Q1 2025 earnings estimates for shares of Bausch Health Companies in a research report issued to clients and investors on Tuesday, June 25th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.83 for the quarter, up from their previous forecast of $0.82. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.63 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q2 2025 earnings at $0.93 EPS, Q3 2025 earnings at $1.13 EPS, FY2025 earnings at $4.19 EPS, Q1 2026 earnings at $1.08 EPS and FY2026 earnings at $5.07 EPS.

Bausch Health Companies (NYSE:BHC) last released its earnings results on Thursday, May 2nd. The company reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.16). Bausch Health Companies had a negative net margin of 5.07% and a negative return on equity of 2,370.91%. The firm had revenue of $2.15 billion for the quarter, compared to analysts’ expectations of $2.18 billion.

A number of other analysts also recently issued reports on BHC. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Piper Sandler lifted their price target on shares of Bausch Health Companies from $7.00 to $9.00 and gave the company a “neutral” rating in a report on Monday, April 29th. Finally, Royal Bank of Canada reduced their price target on shares of Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating on the stock in a report on Tuesday, April 23rd.

Bausch Health Companies Stock Performance

Shares of NYSE BHC opened at $6.89 on Thursday. The company has a market cap of $2.49 billion, a P/E ratio of -5.56 and a beta of 0.82. The firm’s fifty day moving average is $7.03 and its two-hundred day moving average is $8.09. Bausch Health Companies has a 52-week low of $6.05 and a 52-week high of $11.46.

Institutional Trading of Bausch Health Companies

A number of large investors have recently made changes to their positions in BHC. Norges Bank bought a new stake in shares of Bausch Health Companies in the 4th quarter worth about $31,121,000. Hillsdale Investment Management Inc. increased its holdings in shares of Bausch Health Companies by 1,050.8% in the 1st quarter. Hillsdale Investment Management Inc. now owns 3,409,383 shares of the company’s stock worth $36,135,000 after buying an additional 3,113,123 shares during the last quarter. Hudson Bay Capital Management LP grew its holdings in Bausch Health Companies by 35.3% during the 3rd quarter. Hudson Bay Capital Management LP now owns 11,500,000 shares of the company’s stock valued at $94,530,000 after purchasing an additional 3,000,000 shares during the last quarter. SG Americas Securities LLC grew its holdings in Bausch Health Companies by 3,080.9% during the 1st quarter. SG Americas Securities LLC now owns 2,200,526 shares of the company’s stock valued at $23,348,000 after purchasing an additional 2,131,347 shares during the last quarter. Finally, Crestline Management LP bought a new position in Bausch Health Companies during the 4th quarter valued at about $16,040,000. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.